NeuroInvestment today announced the release of its Annual Review Issue covering the neuropharmaceutical sector of drug development, reviewing major events from 2000 and examining prospects for these companies for 2001. In spite of the downturn in many growth sectors, biotech continued to perform well this past year in both its development of new molecules and its fiscal maturation.
2001 will not see the record-breaking moneyraising activity of 2000, but it will see continued progress in the development of cutting-edge treatments for such disorders as Alzheimer’s, Parkinson’s, multiple sclerosis, stroke, brain injury, schizophrenia, and pain. Of particular interest this year will be the announcement of significant progress in the development of neural stem cells, cells being designed to rewire damaged areas of the human brain. This will constitute a core component of the regenerative medicine armamentarium, and regenerative medicine is as groundbreaking as the genomics revolution.
NeuroInvestment has set the standard for reviews of the CNS pharmaceutical industry since 1995. The NeuroInvestment ‘A List’ achieved a mean increase of 63%, following increases of 74% in 1999 and 35% in 1998. The 45 Companies receiving coverage in the 22 page January issue include: Aegera, Axonyx, Apollo, Boston Life Sciences, CeNeS, Centaur, Cephalon (NASDAQ:CEPH), Cognetix, Cortex, Curis, Diacrin, D-Pharm, Elan, Genset, Gliatech, Guilford ,Inotek, Interneuron, Layton Bioscience, MetaPhore, MitoKor, NeoTherapeutics, Neuralstem, Neurobiological Technologies, Neurochem Pharma, Neurocrine Biosciences (NASDAQ:NBIX), Neurogen, NeuroSearch, NPS, Pharmos, Prescient, ReNeuron, Shire (NASDAQ:SHPGY), StemCells, and Titan (AMEX:TTP).
NeuroInvestment is the leading publisher of independent research information regarding companies specializing in the development of therapeutics for neurological/psychiatric disorders. NeuroInvestment is published monthly. Hardcopy and/or electronic delivery available.
Subscription Rates: 3-month trial $120, Individual:1 year $420, 2 year $720. Institutional: 3-month trial $150, 1 year $590, 2 year $1020.. Outside the US/Canada add $30 for hardcopy airmail. New subscribers during January 2001 will also receive the October, November, and December 2000 issues of NI at no cost, covering the topics of Genomics, Stroke, and HIV-dementia, as well as reviewing Genset, Guilford, MitoKor, and Neurobiological Technologies.
